13 September 2017
GENEVA – Programs supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria have saved 22 million lives, according to a report released today. The report also shows significant increases in the number of people receiving treatment for HIV, diagnosis and treatment for TB and having an insecticide treated net to prevent malaria.
The Global Fund Results Report 2017, with cumulative results through the end of 2016, shows a decline of one-third in the number of people dying from AIDS, TB and malaria in the countries where the Global Fund invests.
“Investing in global health is a highly cost effective way to achieve greater security and stability, to protect communities worldwide from infectious disease and to halt emerging health threats,” said Marijke Wijnroks, Interim Executive Director of the Global Fund. “This report highlights outstanding achievements, and also how much more there is to do.”
Programs supported by the Global Fund, which are designed and implemented by local experts and communities affected by the diseases, provided 11 million people with antiretroviral therapy for HIV – more than half the total number of people on treatment worldwide.
Global Fund-supported programs have provided 17.4 million people with testing and treatment for TB, and 795 million mosquito nets to prevent malaria. As a result of prevention and control interventions in more than 100 countries, the Global Fund’s target of averting 140-180 million infections by the end of 2016 was met in 2015.
Since the peak of the crisis, the number of deaths caused by AIDS has declined by 48 percent in countries where the Global Fund invests, from 1.9 million in 2004 to 1 million in 2016. The mortality rate from TB declined 35 percent in countries supported by the Global Fund, and actual deaths declined 21 percent between 2000 and 2015 (excluding HIV-positive people).
As for malaria, which has seen a 50 percent decline in global deaths between 2000 and 2015, cases of malaria treated through Global Fund-supported programs rose 15 percent in the past year alone, to hit a cumulative total of 668 million by end 2016.
“These results show what we can achieve by sticking to our mission and values, but to end the epidemics and build healthier, more prosperous societies we must face the new challenges with courage, including improving the health of adolescent girls and young women and addressing the growing menace of antimicrobial resistance,” Dr. Wijnroks said.
Young people, in particular adolescent girls and young women, still face extraordinary levels of risk; in parts of Africa, young women aged 15-24 years are eight times more likely than their male peers to be living with HIV. To address the inequalities affecting women and girls, the Global Fund’s investments have increased significantly in the past seven years, with about 60 percent of the organization’s total investments now directed to women and girls, the report says.
More than one-third of Global Fund investments go toward building resilient and sustainable systems for health, which are critical to the fight against HIV, TB and malaria, improving the quality of health care overall, and enabling countries to respond to emerging regional and global health threats.
At the same time as investing to fight HIV, TB and malaria, the Global Fund is working with affected countries to increase their own contributions to creating sustainable domestic health programs. The Global Fund’s shared financing requirement stimulates domestic investment in health, which helps ensure the gains are sustainable and builds shared global responsibility for health. The report says to date countries have committed an additional US$6 billion to their health programs for 2015-2017 compared with spending in 2012-2014, representing a 41 percent increase in domestic financing for health.
With affected countries in the lead, the Global Fund partnership, which was set up in 2002, brings together governments, civil society, the private sector and people affected by the diseases to accelerate the end of the epidemics.
+41 79 292 5426